RU2684102C2 - Способ получения лекарственных средств - Google Patents

Способ получения лекарственных средств Download PDF

Info

Publication number
RU2684102C2
RU2684102C2 RU2016139286A RU2016139286A RU2684102C2 RU 2684102 C2 RU2684102 C2 RU 2684102C2 RU 2016139286 A RU2016139286 A RU 2016139286A RU 2016139286 A RU2016139286 A RU 2016139286A RU 2684102 C2 RU2684102 C2 RU 2684102C2
Authority
RU
Russia
Prior art keywords
compound
chloro
methyl
solution
fluorophenyl
Prior art date
Application number
RU2016139286A
Other languages
English (en)
Russian (ru)
Other versions
RU2016139286A3 (OSRAM
RU2016139286A (ru
Inventor
Цзиньгуан ЛИНЬ
Александра ЧЕСТАКОВА
Вэй ГУ
Ханс ИДИНГ
Цзин Ли
Синь ЛИНХУ
Патрик МЕЙЕР
Чуньбо ША
Джеффри СТУЛЬЦ
Ючу ВАН
Хаймин ЧЗАН
Цзяньцянь ЧЗАН
Тао ЧЗАН
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of RU2016139286A publication Critical patent/RU2016139286A/ru
Publication of RU2016139286A3 publication Critical patent/RU2016139286A3/ru
Application granted granted Critical
Publication of RU2684102C2 publication Critical patent/RU2684102C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
RU2016139286A 2014-04-09 2015-04-08 Способ получения лекарственных средств RU2684102C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014075011 2014-04-09
CNPCT/CN2014/075011 2014-04-09
PCT/CN2015/076083 WO2015154674A1 (en) 2014-04-09 2015-04-08 Process for the manufacturing of medicaments

Publications (3)

Publication Number Publication Date
RU2016139286A RU2016139286A (ru) 2018-05-15
RU2016139286A3 RU2016139286A3 (OSRAM) 2018-10-26
RU2684102C2 true RU2684102C2 (ru) 2019-04-04

Family

ID=54287327

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016139286A RU2684102C2 (ru) 2014-04-09 2015-04-08 Способ получения лекарственных средств

Country Status (22)

Country Link
US (4) US20170022183A1 (OSRAM)
EP (2) EP3494971B1 (OSRAM)
JP (3) JP6723926B2 (OSRAM)
KR (3) KR20200038553A (OSRAM)
CN (3) CN106659721B (OSRAM)
AR (1) AR099989A1 (OSRAM)
AU (2) AU2015245743B2 (OSRAM)
BR (2) BR122020014933B8 (OSRAM)
CA (2) CA2945098C (OSRAM)
ES (1) ES2733495T3 (OSRAM)
HR (1) HRP20191306T1 (OSRAM)
IL (2) IL248205B (OSRAM)
MX (2) MX392460B (OSRAM)
MY (3) MY188526A (OSRAM)
NZ (1) NZ725450A (OSRAM)
PL (1) PL3129025T3 (OSRAM)
RU (1) RU2684102C2 (OSRAM)
SG (1) SG11201608421XA (OSRAM)
SI (1) SI3129025T1 (OSRAM)
TW (2) TWI678366B (OSRAM)
WO (1) WO2015154674A1 (OSRAM)
ZA (1) ZA201607066B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2805569C1 (ru) * 2019-12-06 2023-10-19 Дз Байо(Уси) Ко., Лтд. Тиазололактамные соединения в качестве ингибиторов ERK и их применение

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3321262T3 (da) * 2012-03-01 2021-01-25 Array Biopharma Inc Serin-/threoninkinasehæmmere
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015085007A1 (en) 2013-12-06 2015-06-11 Genentech, Inc. Serine/threonine kinase inhibitors
MY188526A (en) 2014-04-09 2021-12-18 Genentech Inc Process for the manufacturing of medicaments
HRP20200342T1 (hr) 2015-11-09 2020-06-12 Astrazeneca Ab Derivati dihidroimidazopirazinona korisni u liječenju raka
AU2017249229A1 (en) 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2019051296A1 (en) 2017-09-08 2019-03-14 Genentech, Inc. DIAGNOSTIC AND THERAPEUTIC METHODS OF CANCER
WO2019158579A1 (en) 2018-02-13 2019-08-22 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
EP3546447A1 (en) * 2018-03-29 2019-10-02 Heidelberg Pharma GmbH Synthesis of (2s,3r,4r)-4,5-dihydroxyisoleucine and derivatives
IL293382A (en) * 2019-12-05 2022-07-01 Astrazeneca Ab Process and intermediates for the production of formula (i)
CN115710158A (zh) * 2021-08-23 2023-02-24 凯特立斯（深圳）科技有限公司 一种不对称催化制备替格瑞洛中间体的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2300377C2 (ru) * 2001-02-09 2007-06-10 Вертекс Фармасьютикалз Инкорпорейтед Гетероциклические ингибиторы erk2 и их использование
WO2015130976A1 (en) * 2014-02-27 2015-09-03 Canon U.S.A., Inc. Placement apparatus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869966B2 (en) * 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives
MX2008012413A (es) * 2006-03-29 2008-10-07 Hoffmann La Roche Derivados de piridina y pirimidina como antagonistas del receptor metabotropico de glutamato 2 (mglur2).
EP2205086B1 (en) * 2007-11-06 2013-08-14 E. I. du Pont de Nemours and Company Fungicidal heterocyclic amines
DK3321262T3 (da) * 2012-03-01 2021-01-25 Array Biopharma Inc Serin-/threoninkinasehæmmere
MY188526A (en) * 2014-04-09 2021-12-18 Genentech Inc Process for the manufacturing of medicaments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2300377C2 (ru) * 2001-02-09 2007-06-10 Вертекс Фармасьютикалз Инкорпорейтед Гетероциклические ингибиторы erk2 и их использование
WO2015130976A1 (en) * 2014-02-27 2015-09-03 Canon U.S.A., Inc. Placement apparatus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RICHARD J. BASTIN ET AL." Salt Selection and Optimisation Procedures for Pharmaceutical Entities", Organic Process Research and Develop, vol.4, N5, 2000, pages 427-435. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2805569C1 (ru) * 2019-12-06 2023-10-19 Дз Байо(Уси) Ко., Лтд. Тиазололактамные соединения в качестве ингибиторов ERK и их применение

Also Published As

Publication number Publication date
US20190367484A1 (en) 2019-12-05
CN111777594B (zh) 2023-06-27
KR20160133566A (ko) 2016-11-22
MY198371A (en) 2023-08-28
US20180134685A1 (en) 2018-05-17
CA2945098C (en) 2022-10-04
US11066389B2 (en) 2021-07-20
EP3129025A4 (en) 2018-01-17
EP3129025A1 (en) 2017-02-15
US20200190061A1 (en) 2020-06-18
EP3129025B1 (en) 2019-05-15
PL3129025T3 (pl) 2019-11-29
KR20230006043A (ko) 2023-01-10
MY188526A (en) 2021-12-18
ES2733495T3 (es) 2019-11-29
BR122020014933B1 (pt) 2022-11-29
CA3167641A1 (en) 2015-10-15
CN112645927A (zh) 2021-04-13
MX2020010384A (es) 2022-05-19
JP2020114817A (ja) 2020-07-30
CN106659721B (zh) 2021-01-01
NZ725450A (en) 2022-08-26
MX2016013162A (es) 2017-04-27
SG11201608421XA (en) 2016-11-29
BR122020014933B8 (pt) 2022-12-13
IL268690A (en) 2019-10-31
AU2020220208B2 (en) 2022-03-17
KR102490955B1 (ko) 2023-01-19
TWI762806B (zh) 2022-05-01
EP3494971C0 (en) 2024-07-24
CA2945098A1 (en) 2015-10-15
IL248205B (en) 2019-09-26
SI3129025T1 (sl) 2019-08-30
AU2015245743A1 (en) 2016-10-27
BR112016023391A8 (pt) 2018-04-17
US20170022183A1 (en) 2017-01-26
ZA201607066B (en) 2018-05-30
IL248205A0 (en) 2016-11-30
TW201620897A (zh) 2016-06-16
MY196320A (en) 2023-03-24
KR20200038553A (ko) 2020-04-13
WO2015154674A1 (en) 2015-10-15
RU2016139286A3 (OSRAM) 2018-10-26
US11098028B2 (en) 2021-08-24
JP6723926B2 (ja) 2020-07-15
CN111777594A (zh) 2020-10-16
MX392460B (es) 2025-03-24
US10611753B2 (en) 2020-04-07
CN106659721A (zh) 2017-05-10
BR112016023391A2 (OSRAM) 2017-08-15
EP3494971A1 (en) 2019-06-12
JP6974524B2 (ja) 2021-12-01
TWI678366B (zh) 2019-12-01
EP3494971B1 (en) 2024-07-24
BR112016023391B1 (pt) 2022-08-09
AU2015245743B2 (en) 2020-09-24
HRP20191306T1 (hr) 2019-10-18
RU2016139286A (ru) 2018-05-15
JP2017510620A (ja) 2017-04-13
AU2020220208A1 (en) 2020-09-10
AR099989A1 (es) 2016-08-31
JP2021167321A (ja) 2021-10-21
TW201945358A (zh) 2019-12-01
MX375638B (es) 2025-03-06

Similar Documents

Publication Publication Date Title
RU2684102C2 (ru) Способ получения лекарственных средств
JP2021119172A (ja) 嚢胞性線維症膜コンダクタンス制御因子の調節物質、医薬組成物、治療方法、及び調節物質の作製プロセス
WO2013115162A1 (ja) シタキセンタン誘導体
HK40039714A (en) Process for the manufacturing of medicaments
HK40039714B (zh) 用於制备药物的方法
HK40007970B (en) Salts of erk inhibitors
HK40007970A (en) Salts of erk inhibitors
HK1233931A1 (en) Process for the manufacturing of medicaments
HK1233931B (en) Process for the manufacturing of medicaments
NZ761260A (en) Crystalline salts of erk inhibitors
AU2023225437A1 (en) Indazole compound and pharmaceutical use thereof
WO2020143800A1 (zh) 肝脏特异性ampk激动剂及其制法和应用